Vivus settles patent litigation case with Dr Reddy's

In 2015, Vivid filed a patent infringement case against Dr Reddy's

premium

Novartis is addressing the pricing question with a new type of agreement: For patients whose care is covered by the US govt programmes, the company will only get paid if patients show signs that the treatment is working within a month | Photo: istock

BS Reporter Hyderabad

Last Updated : Sep 01 2017 | 2:49 PM IST

American pharmaceutical company Vivus, Inc has entered into a settlement agreement with Dr Reddy's Laboratories Limited's US subsidiaries in a patent litigation involving it's weight management drug Qsymia.

In 2015, Vivid filed a patent infringement case against Dr Reddy's after the latter filed an application to the US Food and Drug Administration (USFDA) for approval to launch a generic version of this drug.

The settlement agreement permits Dr Reddy's to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of the generic version of Qsymia, the company said in a statement.

Qsymia is approved in the US and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

Dr Reddy's scrip was up 8.49 percent or Rs 171.50 at Rs 2191.90 in the morning trade on Bombay Stock Exchange.